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What is the best approach 
to the evaluation of hirsutism?
■ Evidence summary
Hirsutism is the presence of excess terminal
hairs in androgen-dependent areas on a
female, and can be measured objectively
using a scoring system such as the modified
Ferriman-Gallway (mF-G) score. This test is
done by adding hair scores (0=none,
4=frankly virile) in 9 different body loca-
tions. A total score >8 is considered hirsute.
The incidence of hirsutism in the US is
about 8%, based on a prospective study of
369 consecutive women of reproductive age
seeking pre-employment physicals in the
southeastern US using the mF-G criteria.1
The causes of clinically apparent
androgen excess, including acne and hir-
sutism, were evaluated in 1281 consecutive
patients presenting to a university endo-
crinology clinic.2 Researchers excluded 408
subjects due to the inability to assess 
hormone status or ovulatory function. The
remaining 873 women were assessed by
clinical exam, mF-G score, serum total and
free testosterone, DHEAS, and 17-hydroxy-
Early work on expectations by physician 
and patient leads to a better outcome
Primary care physicians field questions about non-
specific findings on a day-to-day basis. Hirsutism is a
common complaint and physical finding in women.
Most diagnoses related to hirsutism are not life-
threatening and have a relatively straightforward
workup. There is the occasional patient with a zebra-
type diagnosis that demands more detailed evalua-
tion. As with most physical findings that have a large
subjective component, I find that early management
of expectations both on the part of the physician and
patient leads to a better outcome whether or not a
million-dollar workup shows any definitive pathology. 
Tim Huber, MD 
Naval Hospital, Camp Pendleton, Calif
The evaluation of hirsutism should begin with a
history and physical examination to identify signs
and symptoms suggestive of diseases such as
polycystic ovarian syndrome (PCOS), hypo-
thyroidism, hyperprolactinemia, hyperandrogenic
insulin-resistant acanthosis nigricans (HAIR-AN)
syndrome, androgenic tumors, Cushing’s 
syndrome, or congenital adrenal hyperplasia
(CAH). Findings suggestive of these diseases
include rapid or early-onset hirsutism, menstrual
irregularities, hypertension, severe hirsutism, viril-
ization, or pelvic masses (strength of recommenda-
tion [SOR]: B, based on a cohort study in a referral
population) (TABLE). Hirsutism with unremarkable
history and physical exam findings should be eval-
uated with a serum total testosterone and dehy-
droepiandrosterone sulfate (DHEAS) level (SOR: B,
based on a cohort study in a referral population).
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With an 
unremarkable 
history and exam,
order serum total
testosterone and
dehydroepi-
androsterone 
sulfate levels
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progesterone (17-HP). Hyperandrogenism
was defined as an androgen value above the
95th percentile of 98 healthy control
women (total testosterone ≥88 ng/dL, free
testosterone ≥0.75 ng/dL, or DHEAS ≥2750
ng/dL). Those with a 17-HP level >2 ng/mL
had either a repeat 17-HP or adrenocorti-
cotropic hormone (ACTH) stimulation test.
Those with at least 2 total testosterone lev-
els above 250 ng/dL or those with signs of
an androgen-secreting neoplasm (eg, viril-
ization) underwent a transvaginal sono-
gram and a CT scan of the adrenals.
Patients with ovulatory dysfunction had a
thyroid-stimulating hormone (TSH) and
prolactin level drawn. If Cushing’s syn-
drome was suspected clinically, the subjects
underwent an overnight 1-mg dexametha-
sone suppression test (TABLE). Of 873
patients, 75.5% had hirsutism and 77.8%
had hyperandrogenemia. An identifiable
disorder of androgen excess was found in
7%; functional androgen excess (principal-
ly PCOS) was identified in the remainder.
The incidence of endocrine disorders
among patients presenting with hirsutism
or androgenic alopecia was evaluated dur-
ing a prospective study of 350 consecutive
patients referred to an endocrine clinic in
the UK.3 Testing included serum total
testosterone, androstenedione, 17-HP, and
DHEAS on 2 occasions. Patients also
underwent high-resolution pelvic ultra-
sound. Further investigations were done
only for those with abnormal hormone lev-
els or clinical findings suggestive of a
tumor. Of 350 women tested, 13 had a
markedly elevated serum total testosterone
level >5 nmol/L (150 ng/dL). A single total
testosterone test identified 6 of 8 patients
with an underlying endocrine disorder. The
other 2 had either acromegaly or prolactin-
oma. The researchers concluded that clini-
cal assessment and a single serum total
testosterone level were sufficient to exclude
enzyme deficiencies and virilizing tumors.
A retrospective study of 84 consecutive
women presenting to an endocrinology
clinic in the Netherlands was conducted to
determine hormone level sensitivity and
specificity to identify virilizing adrenal
tumors.4 Hormone levels of 14 women
with either an adrenal carcinoma (n=12) or
an adrenal adenoma (n=2) were compared
with the hormone levels of the women with
hirsutism (n=73) as well as to the controls
(n=31). Serum levels of total testosterone,
androstenedione, DHEAS, DHEA, and
cortisol were measured. A 24-hour urinary
17-ketosteroid excretion was also meas-
ured. A 5-day dexamethasone suppression
study was conducted and a urinary sample
was obtained between 8 and 9 A.M. on Day
6. An elevated basal total testosterone (nor-
mal range, 29–84 ng/dL) or DHEAS level
(normal range, 118–431 ng/dL) detected all
14 women with adrenal carcinomas or ade-
nomas and 36 of 73 women with hirsutism
of non-neoplastic origin. The combined test
sensitivity was 100% (95% confidence
interval [CI], 77–100) and specificity was
50% (95% CI, 38–62) for the detection of
adrenal tumors. 
A prospective study of the incidence of
late-onset CAH among hirsute women
evaluated 83 consecutive patients with hir-
sutism from an endocrinology clinic in
California with an ACTH stimulation test.5
They found 1 patient with late-onset CAH.
Because CAH had an incidence of only
1.2% (95% CI, 0.0–3.4), the authors con-
cluded that routine testing with the ACTH
stimulation test is not cost-effective for the
evaluation of hirsutism. 
Recommendations from others 
The American College of Obstetrics and
Gynecology 1995 technical bulletin recom-
mended using the clinical examination to
guide the evaluation, and laboratory testing
to rule out androgen-producing tumors
including a serum total testosterone and
DHEAS.6 The Society of Obstetricians and
Gynaecologists of Canada advised using the
clinical examination to guide the assess-
ment, and a total serum testosterone level
and a DHEAS level.7
Referral is recommended in the 
presence of virilism or if the total testos-
terone or DHEAS level is over twice the
upper limit of normal or if there are signs of
Cushing’s disease. 
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T A B L E
DIAGNOSIS INCIDENCE KEY HISTORY/EXAM FINDINGS ADDITIONAL TESTING
Polycystic ovarian syndrome 82.0% ± irregular menses, slow-onset Fasting glucose, insulin and lipid 
hirsutism, obesity, infertility, diabetes, profile, blood pressure, ultrasound 
hypertension, family history of PCOS, positive for multiple ovarian cysts 
diabetes
Hyperandrogenism with 6.8% Regular menses, acne, hirsutism Elevated androgen levels and normal
hirsutism, normal ovulation without detectable endocrine cause serum progesterone in luteal phase
Idiopathic hirsutism 4.7% Regular menses, hirsutism, possible Normal androgen levels, normal 
overactive 5 alpha-reductase activity serum progesterone in luteal phase
in skin and hair follicle
Hyperandrogenic insulin- 3.1% Brown velvety patches of skin Fasting glucose and lipid profile, 
resistant acanthosis (acanthosis nigricans), obesity, BP, fasting insulin level >80 µIU/mL 
nigricans (HAIR-AN) hypertension, hyperlipidemia, strong or insulin level >300  on 3-hour
family history of diabetes glucose tolerance test
21-hydroxylase non-classic 1.6% Severe hirsutism or virilization, 17-HP level before and after ACTH 
adrenal hyperplasia strong family history of CAH, stimulation test >10 ng/dL, CYP21 
(late-onset CAH) short stature, signs of defeminization, genotyping.
more common in Ashkenazi Jews 
and Eastern European decent
21-hydroxylase-deficient 0.7% See Late-onset CAH. 17-HP levels >30 ng/dL
congenital adrenal Congenital virilization
hyperplasia
Hypothyroidism 0.7%* Fatigue, weight gain, history of TSH
thyroid ablation and untreated 
hypothyroidism, amenorrhea
Hyperprolactinemia 0.3%† Amenorrhea, galactorrhea, infertility Prolactin
Androgenic secreting 0.2% Pelvic masses, rapid-onset hirsutism Pelvic ultrasound or 
neoplasm or virilization, over age 30 with abdomen/pelvic CT scan 
onset of symptoms
Cushing’s syndrome 0%‡ Hypertension, buffalo hump, Elevated blood pressure, positive 
purple striae, truncal obesity dexamethasone suppression test
Differential diagnosis of clinically apparent androgen excess
*Five patients were previously diagnosed with hypothyroidism and 1
patient was diagnosed as part of the work-up for a total prevalence of
6 in 873 or 0.7% although the de novo incidence was only 0.1%.
†Two patients were previously diagnosed with hyperprolactinemia
and 1 was detected during the work-up for a total prevalence of 3 in
873 or 0.3% although the de novo incidence was 0.1%.
‡No patients were identified with Cushing’s syndrome in this study.
Other published reports vary from 0-1% (3).
Source: Azziz et al, J Clin Endocrinol Metab 20042; Azziz, Obstet
Gynecol 2003.8
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